Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tissue Repair Ltd (TRP.AX)
Chatswood, NSW, AU
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -8.33% | -15.38% | -38.89% | -62.07% | -71.43% | -40.54% | -60.71% | -84.17% | -84.17% | -84.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+1,629.7% ★ Q4'25: +422.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-2.5% Q4'25: +3.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-156.5% Q4'25: -547.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-183.2% Q4'25: -1,107.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-302.9% Q4'25: -254.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. |
|---|---|---|---|---|---|
| Revenue |
171.9K
est: 800.0K (-78.5%)
|
3.1K
est: 440.0K (-99.3%)
|
152.2K
est: 3.59M (-95.8%)
|
2.63M
est: 8.23M (-68.0%)
|
7.18M
7.18M – 7.18M
-12.8% YoY
|
| EBITDA |
-7.01M
est: -800.0K (-776.0%)
|
-5.14M
est: -440.0K (-1,068.3%)
|
-6.51M
est: -3.59M (-81.5%)
|
-4.72M
est: -8.23M (+42.6%)
|
-7.18M
-7.18M – -7.18M
+12.8% YoY
|
| EBIT |
-7.01M
est: -800.0K (-776.2%)
|
-5.14M
est: -440.0K (-1,068.9%)
|
-6.52M
est: -3.59M (-81.5%)
|
-4.83M
est: -8.23M (+41.4%)
|
-7.18M
-7.18M – -7.18M
+12.8% YoY
|
| Net Income |
-6.84M
est: -2.54M (-169.2%)
|
-4.17M
est: -2.90M (-43.8%)
|
-4.14M
est: -6.11M (+32.2%)
|
-4.24M
est: -4.72M (+10.1%)
|
—
— – —
+100.0% YoY
|
| SGA |
2.80M
est: 169.82M (-98.3%)
|
3.13M
est: 93.40M (-96.7%)
|
3.43M
est: 762.07M (-99.5%)
|
3.31M
est: 1.75B (-99.8%)
|
1.52B
1.52B – 1.52B
-12.8% YoY
|
| EPS |
-0.11
est: -0.04 (-161.9%)
|
-0.07
est: -0.05 (-43.8%)
|
-0.07
est: -0.10 (+32.3%)
|
-0.07
est: -0.08 (+10.1%)
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tony Charara | Co-Founder, Chief Executive Officer & Executive Director | 200.0K | male |
| Darryl Reed | Chief Operating Officer | — | — |
| Dion Cohen | Chief Financial Officer | — | male |
| Peter D. A. Scutt | Executive Director | — | male |
| Sushma Kejriwal | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRP.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
